Association
Quotient Clinical hosts European Pharmaceutical Aerosol Group (EPAG) meeting
Quotient are delighted to host a gathering of inhaled medicine experts at the next European Pharmaceutical Aerosol Group (EPAG) meeting.
6 / 9 articles displayed
-
-
Association
Ironshore Pharmaceuticals enters into an agreement with Quotient Clinical to conduct scintigraphy imaging of a new drug candidate
Agreement with Quotient Clinical Expands Pipeline Beyond Neuroscience Franchise Proof of Concept Study Designed to Demonstrate Preferential Delivery of Drug to Initial Site of Damage in IBD to Position HLD-400 as Potential First-Line Therapy.
-
Association
Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs
Quotient Sciences, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges. This venture willcombine Upperton’s formulation development services with Quotient’s GMP manufacturingservices.
-
Association
MEI Pharma announces new clinical data from First-In-Human Study of ME-401
MEI Pharma, the San Diego based oncology company, have today announced new clinical data from a First-In-Human study for ME-401, a next generation oral PI3K delta inhibitor.
-
Association
Quotient Clinical begins prostate cancer project for Druggability Technologies
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the initiation of a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate, a marketed drug prescribed in combination with prednisone to patients suffering from metastatic prostate cancer.
-
Association
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated, focusing on a next generation selective glucocorticoid receptor antagonist (CORT125134) in development for the treatment of Cushing’s syndrome and certain cancers.